Liver Cancer pp 145-158 | Cite as

Hepatocellular Carcinoma: Contrast-Enhanced Sonography

  • Byung Ihn Choi
  • Se Hyung Kim
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 5)

In patients with chronic liver disease, sono-graphy and measurements of serum alpha-fetoprotein (αFP) levels are frequently used to screen for hepatocellular carcinoma (HCC). The sensitivity of sonography for HCC detection, however, in the end-stage cirrhotic liver is only 50% (Dodd et al., 1992). Furthermore, sonographic findings of HCC are variable and frequently nonspecific. Hepatocellular carcinoma is highly vascularized and often shows irregular neovascularization within the tumor. Therefore, detection and characterization of tumor vascularity are important in the differential diagnosis, the choice of treatment method, and assessment of the therapeutic response for HCC. Although color and power Doppler sonography are helpful in detecting vascularity of hepatic tumors, it has not proved satisfactory.

Since intravenous microbubble contrast agents including SH U 508A (Levovist; Schering AG, Berlin, Germany) for sonography have become available, many researchers have reported that contrast-enhanced sonography could be a promising technique for assessing post-treatment response of HCC (Bartolozzi et al., 1998; Choi, D. et al., 2000; Ding et al., 2001; Meloni et al., 2001; Solbiati et al., 1999; Youk et al., 2003b) as well as for making a correct diagnosis of HCC by observing tumoral vascularity (Choi et al., 2000a; Dill-Macky et al., 2002; Kim et al., 1998; Wen et al., 2004). Indeed, there is an increasing consensus that the use of contrast agents improves the ability of sonography to detect and characterize focal hepatic lesions. Levovist, one of the most popular sonographic contrast agents, is a suspension of galactose microparticles in sterile water. The microbubbles (2–8 μm in diameter, with a mean of 3 μm), which are stabilized in the microparticle suspension, can traverse the pulmonary capillary bed and diverse into whole blood circulation (Kim et al., 1998).

Keywords

Contrast Agent Percutaneous Ethanol Injection Mechanical Index Ultrasound Contrast Agent Power Doppler Sonography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartolozzi, C., Lencioni, R., Ricci, P., Paolicchi, A., Rossi, P., and Passariello, R. 1998. Hepatocellular carcinoma treatment with percutaneous etha-nol injection: evaluation with contrast-enhanced color Doppler US. Radiology 209:387–393.PubMedGoogle Scholar
  2. Burns, P.N. 1996. Harmonic imaging with ultrasound contrast agents. Clin. Radiol. 51: Suppl. 1:50–55.PubMedGoogle Scholar
  3. Choi, B.I., Kim, T.K., Han, J.K., Chung, J.W., Park, J.H., and Han, M.C. 1996. Power versus conventional color Doppler sonography: comparison in the depiction of vasculature in liver tumors. Radiology 200:55–58.PubMedGoogle Scholar
  4. Choi, B.I., Kim, T.K., Han, J.K., Kim, A.Y., Seong, C.K., and Park, S.J. 2000a. Vascularity of hepa-tocellular carcinoma: assessment with contrast-enhanced second-harmonic versus conventional power Doppler US. Radiology 214:381–386.Google Scholar
  5. Choi, D., Lim, H.K., Kim, S.H., Lee, W.J., Jang, H.J., Lee, J.Y., Paik, S.W., Koh, K.C., and Lee, J.H. 2000b. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results. Radiology 217:558–563.Google Scholar
  6. Choi, D., Lim, H.K., Lee, W.J., Kim, S.H., Kim, Y.H., Kim, S.H., and Lim, J.H. 2003. Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultrasonography with a microbubble contrast agent. J. Ultrasound Med. 22:1163–1172.PubMedGoogle Scholar
  7. Dill-Macky, M.J., Burns, P.N., Khalili, K., and Wilson, S.R. 2002. Focal hepatic masses: enhancement patterns with SH U 508A and pulse-inversion US. Radiology 222:95–102.PubMedCrossRefGoogle Scholar
  8. Ding, H., Kudo, M., Onda, H., Suetomi, Y., Minami, Y., Chung, H., Kawasaki, T., and Maekawa, K. 2001. Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 221:721–730.PubMedCrossRefGoogle Scholar
  9. Dodd, G.D. III, Miller, W.J., Baron, R.L., Skolnick, M.L., and Campbell, W.L. 1992. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. AJR Am. J. Roentgenol. 159:727–733.PubMedGoogle Scholar
  10. Ernst, H., Hahn, E.G., Balzer, T., Schlief, R., and Heyder, N. 1996. Color Doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist. J. Clin. Ultrasound 24:31–35.PubMedCrossRefGoogle Scholar
  11. Goldberg, S.N., Gazelle, G.S., Compton, C.C., Mueller, P.R., and Tanabe, K.K. 2000. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 88:2452–2463.PubMedCrossRefGoogle Scholar
  12. Gramiak, R., and Shah, P.M. 1968. Echocardiography of the aortic root. Invest. Radiol. 3:356–366.PubMedCrossRefGoogle Scholar
  13. Hohl, C., Schmidt, T., Haage, P., Honnef, D., Blaum, M., Staatz, G., and Guenther, R.W. 2004. Phase-inversion tissue harmonic imaging compared with conventional B-mode ultrasound in the evaluation of pancreatic lesions. Eur. Radiol. 14:1109–1117.PubMedCrossRefGoogle Scholar
  14. Jang, H.J., Lim, H.K., Lee, W.J., Kim, S.H., Kim, K.A., and Kim, E.Y. 2000. Ultrasonographic evaluation of focal hepatic lesions: comparison of pulse inversion harmonic, tissue harmonic, and conventional imaging techniques. J. Ultrasound Med. 19:293–299.PubMedGoogle Scholar
  15. Kim, A.Y., Choi, B.I., Kim, T.K., Han, J.K., Yun, E.J., Lee, K.Y., and Han, M.C. 1998. Hepatocellular carcinoma: power Doppler US with a contrast agent—preliminary results. Radiology 209:135–140.PubMedGoogle Scholar
  16. Kim, C.K., Choi, D., Lim, H.K., Kim, S.H., Lee, W.J., Kim, M.J., Lee, J.Y., Jeon, Y.H., Lee, J., Lee, S.J., and Lim, J.H. 2005a. Therapeutic response assessment of percutaneous radiofre-quency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur. J. Radiol. 56:66–73.CrossRefGoogle Scholar
  17. Kim, K.W., Choi, B.I., Park, S.H., Kim, H.C., Lee, M.W., Kim, S.H., Lee, K.H., Park, C.H., Kim, J.S., Won, H.J., and Han, J.K. 2003. Hepatocellular carcinoma: assessment of vascu-larity with single-level dynamic ultrasonography during the arterial phase. J. Ultrasound Med. 22:887–896.PubMedGoogle Scholar
  18. Kim, S.H., Lee, J.M., Lee, J.Y., Han, J.K., An, S.K., Han, C.J., Lee, K.H., Hwang, S.S., and Choi, B.I. 2005b. Value of contrast-enhanced sonography for the characterization of focal hepatic lesions in patients with diffuse liver disease: receiver operating characteristic analysis. AJR Am. J. Roentgenol. 184:1077–1084.Google Scholar
  19. Kim, T.K., Han, J.K., Kim, A.Y., Park, S.J., and Choi, B.I. 1999. Signal from hepatic hemangi-omas on power Doppler US: real or artefactual? Ultrasound Med. Biol. 25:1055–1061.PubMedCrossRefGoogle Scholar
  20. Kim, T.K., Choi, B.I., Han, J.K., Hong, H.S., Park, S.H., and Moon, S.G. 2000. Hepatic tumors: contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology 216:411–417.PubMedGoogle Scholar
  21. Lee, J.Y., Choi, B.I., Han, J.K., Kim, A.Y., Shin, S.H., and Moon, S.G. 2002. Improved sono-graphic imaging of hepatic hemangioma with contrast-enhanced coded harmonic angiography: comparison with MR imaging. Ultrasound Med. Biol. 28:287–295.PubMedCrossRefGoogle Scholar
  22. Lee, J.Y., Choi, B.I., Han, J.K., Kim, A.Y., Shin, S.H., and Park, C.M. 2003. Assessment of hepatocellular carcinoma vascularity: comparison of contrast-enhanced coded harmonic ultrasound with harmonic power Doppler ultrasound. J. Med. Ultrasound 11:147–155.CrossRefGoogle Scholar
  23. Lencioni, R., Caramella, D., and Bartolozzi, C. 1995. Hepatocellular carcinoma: use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology 194:113–118.PubMedGoogle Scholar
  24. Lencioni, R., Pinto, F., Armillotta, N., and Bartolozzi, C. 1996. Assessment of tumor vascu-larity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US. Radiology 201:353–358.PubMedGoogle Scholar
  25. Meloni, M.F., Goldberg, S.N., Livraghi, T., Calliada, F., Ricci, P., Rossi, M., Pallavicini, D., and Campani, R. 2001. Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am. J. Roentgenol. 177:375–380.PubMedGoogle Scholar
  26. Porter, T.R., Xie, F., Kricsfeld, D., and Armbruster, R.W. 1996. Improved myocardial contrast with second harmonic transient ultrasound response imaging in humans using intravenous perfluor-ocarbon-exposed sonicated dextrose albumin. J. Am. Coll. Cardiol. 27:1497–1501.PubMedCrossRefGoogle Scholar
  27. Rossi, S., Di, S.M., Buscarini, E., Quaretti, P., Garbagnati, F., Squassante, L., Paties, C.T., Silverman, D.E., and Buscarini, L. 1996. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am. J. Roentgenol. 167:759–768.PubMedGoogle Scholar
  28. Schneider, M. 1999. SonoVue, a new ultrasound contrast agent. Eur. Radiol. 9: Suppl. 3:S347–S348.PubMedCrossRefGoogle Scholar
  29. Schneider, M., Arditi, M., Barrau, M.B., Brochot, J., Broillet, A., Ventrone, R., and Yan, F. 1995. BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbub-bles. Invest. Radiol. 30:451–457.PubMedCrossRefGoogle Scholar
  30. Solbiati, L., Goldberg, S.N., Ierace, T., Dellanoce, M., Livraghi, T., and Gazelle, G.S.1999. Radio-frequency ablation of hepatic metastases: post-procedural assessment with a US microbubble contrast agent—early experience. Radiology 211:643–649.PubMedGoogle Scholar
  31. Strobel, D., Krodel, U., Martus, P., Hahn, E.G., and Becker, D. 2000. Clinical evaluation of contrast-enhanced color Doppler sonography in the differential diagnosis of liver tumors. J. Clin. Ultrasound 28:1–13.PubMedCrossRefGoogle Scholar
  32. Tanaka, S., Kitamra, T., Fujita, M., and Yoshioka, F. 1998. Value of contrast-enhanced color Doppler sonography in diagnosing hepatocellular carcinoma with special attention to the “color-filled pattern”. J. Clin. Ultrasound 26:207–212.PubMedCrossRefGoogle Scholar
  33. Tanaka, S., Kitamura, T., Fujita, M., Nakanishi, K., and Okuda, S. 1990. Color Doppler flow imaging of liver tumors. AJR Am. J. Roentgenol. 154:509–514.PubMedGoogle Scholar
  34. von Herbay, A., Vogt, C., Willers, R., and Haussinger, D. 2004. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J. Ultrasound Med. 23:1557–1568.Google Scholar
  35. Wen, Y.L., Kudo, M., Zheng, R.Q., Ding, H., Zhou, P., Minami, Y., Chung, H., Kitano, M., Kawasaki, T., and Maekawa, K. 2004. Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am. J. Roentgenol. 182:1019–1026.PubMedGoogle Scholar
  36. Youk, J.H., Kim, C.S., and Lee, J.M. 2003a. Contrast-enhanced agent detection imaging: value in the characterization of focal hepatic lesions. J. Ultrasound Med. 22:897–910.Google Scholar
  37. Youk, J.H., Lee, J.M., and Kim, C.S. 2003b. Therapeutic response evaluation of malignant hepatic masses treated by interventional procedures with contrast-enhanced agent detection imaging. J. Ultrasound Med. 22:911–920.Google Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  • Byung Ihn Choi
    • 1
  • Se Hyung Kim
    • 1
  1. 1.Department of RadiologySeoul National University College of MedicineSeoulKorea

Personalised recommendations